KEYNOTE-040 evaluates pembrolizumab in head and neck cancer

(European Society for Medical Oncology) Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy, according to results of the Keynote-040 trial presented at the ESMO 2017 Congress in Madrid.